Helmholtz Gemeinschaft


Vitronectin concentrations predict risk in patients undergoing coronary stenting

Item Type:Article
Title:Vitronectin concentrations predict risk in patients undergoing coronary stenting
Creators Name:Derer, W., Barnathan, E.S., Safak, E., Agarwal, P., Heidecke, H., Moeckel, M., Gross, M., Oezcelik, C., Dietz, R. and Dechend, R.
Abstract:BACKGROUND: Vitronectin is a multifunctional protein with a multiple binding domain that interacts with a variety of plasma and cell proteins. Vitronectin binds multiple ligands, including the soluble vitronectin receptor. Abciximab binds equally well to soluble vitronectin receptor and glycoprotein IIb/IIIa, because both share the beta(3) subunit. We tested whether vitronectin concentrations correlate with adverse outcomes in acute coronary syndrome patients. METHODS AND RESULTS: Baseline serum samples (n=233) from a randomized, placebo-controlled trial of abciximab plus stenting (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting EPISTENT) were retrospectively analyzed. We stratified vitronectin concentrations into the 3 lower quartiles (n=178; <49.7 microg/mL) versus the fourth upper quartile (n=55; >or=49.7 microg/mL). The end point was a major adverse cardiovascular event defined as death, myocardial infarction or urgent revascularization at 30 days and 6 months. A higher proportion of patients with baseline vitronectin >or=49.7 microg/mL had major adverse cardiovascular event than patients with baseline vitronectin <49.7 microg/mL at 30 days (18.2% versus 5.6%; P=0.01) and 6 months (20.0% versus 6.2%; P=0.006). When baseline variables not predictive of major adverse cardiovascular event (eg, troponin positive, history of congestive heart failure, diabetes, history of hypertension, smoking status) were excluded from the multivariate model, only baseline vitronectin >or=49.7 microg/mL (at 30 days: OR, 3.23; 95% CI, 1.23, 8.49; at 6 months: OR, 3.36; 95% CI, 1.33, 8.52) and history of myocardial infarction (at 30 days: OR, 5.02; 95% CI, 1.41, 17.9; at 6 months: OR, 3.99; 95% CI, 1.28, 12.43) remained. No interaction occurred between abciximab and vitronectin. CONCLUSIONS: Our findings indicate that vitronectin may be an independent predictor of adverse cardiovascular outcomes following acute stenting.
Keywords:Risk Factors, Vitronectin, Stents, Glycoproteins IIb-IIIa
Source:Circulation Cardiovascular Interventions
Publisher:Lippincott Williams & Wilkins
Page Range:14-19
Date:February 2009
Official Publication:https://doi.org/10.1161/CIRCINTERVENTIONS.108.795799
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library